loading
Chemomab Therapeutics Ltd Adr stock is traded at $1.58, with a volume of 31,133. It is down -4.57% in the last 24 hours and down -3.99% over the past month. Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
See More
Previous Close:
$1.64
Open:
$1.65
24h Volume:
31,133
Relative Volume:
0.14
Market Cap:
$31.30M
Revenue:
-
Net Income/Loss:
$-33.08M
P/E Ratio:
-0.5374
EPS:
-2.94
Net Cash Flow:
$-25.68M
1W Performance:
-10.06%
1M Performance:
-3.99%
6M Performance:
+90.85%
1Y Performance:
+213.63%
1-Day Range:
Value
$1.5551
$1.68
1-Week Range:
Value
$1.54
$1.79
52-Week Range:
Value
$0.42
$2.55

Chemomab Therapeutics Ltd Adr Stock (CMMB) Company Profile

Name
Name
Chemomab Therapeutics Ltd Adr
Name
Phone
972-77-331-0156
Name
Address
KIRYAT ATIDIM, BUILDING 7, TEL AVIV
Name
Employee
20
Name
Twitter
Name
Next Earnings Date
2024-11-14
Name
Latest SEC Filings
Name
CMMB's Discussions on Twitter

Compare CMMB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
CMMB 1.58 31.30M 0 -33.08M -25.68M -2.94
VRTX 448.66 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.45 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 588.56 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.89 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.27 24.49B 3.30B -501.07M 1.03B 11.54

Chemomab Therapeutics Ltd Adr Stock (CMMB) Latest News

pulisher
Nov 19, 2024

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis - GlobeNewswire Inc.

Nov 19, 2024
pulisher
Oct 15, 2024

Chemomab reports progress in PSC treatment trial - Investing.com

Oct 15, 2024
pulisher
Sep 20, 2024

Roth MKM Initiates Coverage of Chemomab Therapeutics LtdADR (CMMB) with Buy Recommendation - MSN

Sep 20, 2024
pulisher
Sep 16, 2024

The Chemomab Therapeutics Ltd ADR (CMMB) had a good session last reading, didn’t it? - US Post News

Sep 16, 2024
pulisher
Sep 13, 2024

Financial Health Check: Examining Chemomab Therapeutics Ltd ADR (CMMB)’s Key Ratios - The Dwinnex

Sep 13, 2024
pulisher
Sep 09, 2024

Chemomab Therapeutics Ltd ADR (CMMB) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle

Sep 09, 2024
pulisher
Sep 09, 2024

Ratios Uncovered: Breaking Down Chemomab Therapeutics Ltd ADR (CMMB)’s Trailing Twelve Months Metrics - The Dwinnex

Sep 09, 2024
pulisher
Sep 04, 2024

Is Chemomab Therapeutics Ltd ADR (CMMB) a good investment opportunity? - US Post News

Sep 04, 2024
pulisher
Sep 03, 2024

CMMB stock touches 52-week high at $2.07 amid market fluctuations - Investing.com

Sep 03, 2024
pulisher
Aug 27, 2024

Chemomab Therapeutics Ltd ADR (CMMB) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle

Aug 27, 2024
pulisher
Aug 27, 2024

Are Chemomab Therapeutics Ltd ADR (CMMB) shares a good deal now? - US Post News

Aug 27, 2024
pulisher
Aug 26, 2024

CMMB stock touches 52-week high at $1.58 amid market fluctuations - Investing.com India

Aug 26, 2024
pulisher
Aug 23, 2024

Chemomab Therapeutics Ltd ADR (CMMB) Stock: Uncovering 52-Week Market Trends - The InvestChronicle

Aug 23, 2024
pulisher
Jul 26, 2024

Market Analysts see American Express Co. [AXP] gaining to $265. Time to buy? - The DBT News

Jul 26, 2024
pulisher
Jul 26, 2024

Chemomab Therapeutics Ltd ADR [CMMB] moved down -16.20: Why It’s Important - The DBT News

Jul 26, 2024
pulisher
Jul 26, 2024

Chemomab regains Nasdaq compliance with bid price rule - Investing.com

Jul 26, 2024
pulisher
Jul 26, 2024

Public Service Enterprise Group Inc. [PEG] Revenue clocked in at $9.72 billion, up 21.41% YTD: What’s Next? - The DBT News

Jul 26, 2024
pulisher
Jul 26, 2024

Cerevel Therapeutics Holdings Inc [CERE] Is Currently 2.37 below its 200 Period Moving Avg: What Does This Mean? - The DBT News

Jul 26, 2024
pulisher
Jul 26, 2024

Ardelyx Inc [ARDX] moved down -2.31: Why It’s Important - The DBT News

Jul 26, 2024
pulisher
Jul 25, 2024

CMMB’s 2023 Market Dance: Up 107.84% – Time to Invest? - The InvestChronicle

Jul 25, 2024
pulisher
Jul 25, 2024

Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise - Benzinga

Jul 25, 2024
pulisher
Jul 25, 2024

Chemomab secures $10 million in PIPE financing - Investing.com India

Jul 25, 2024
pulisher
Jun 29, 2024

Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy? - Yahoo News Malaysia

Jun 29, 2024
pulisher
Jun 27, 2024

Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know - MSN

Jun 27, 2024
pulisher
May 17, 2024

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences - Investing.com India

May 17, 2024
pulisher
Apr 24, 2024

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update - Investing.com India

Apr 24, 2024
pulisher
Mar 26, 2024

LGVN Stock Quote Price and Forecast - CNN

Mar 26, 2024
pulisher
Feb 14, 2024

symbol__ Stock Quote Price and Forecast - CNN

Feb 14, 2024
pulisher
Dec 06, 2023

Why Copart, Inc. (CPRT) is a Top Momentum Stock for the Long-Term - Zacks Investment Research

Dec 06, 2023
pulisher
Jul 12, 2023

Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight - PR Newswire

Jul 12, 2023
pulisher
Dec 03, 2021

Chemomab Stock: Leading Anti-CCL24 mAb For Fibrotic Diseases (NASDAQ:CMMB) - Seeking Alpha

Dec 03, 2021
pulisher
Jun 24, 2021

Chemomab And AGC Biologics Partner To Manufacture CM-101 For Phase II/III - Contract Pharma

Jun 24, 2021
pulisher
Mar 23, 2021

Chemomab Therapeutics (CMMB) Stock Price, News & Analysis - MarketBeat

Mar 23, 2021
pulisher
Mar 18, 2021

Chemomab Therapeutics (NASDAQ:CMMB) Stock Quotes, Forecast and News Summary - Benzinga

Mar 18, 2021
pulisher
Dec 16, 2020

The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal - Yahoo Finance

Dec 16, 2020

Chemomab Therapeutics Ltd Adr Stock (CMMB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):